

CD274/PD-L1 recombinant protein

CatalogNo: YD3058

Key Features

Reactivity

- Human,

Recommended Dilution Ratios

Storage

Storage* -15°C to -25°C/1 year(Avoid freeze / thaw cycles)

Formulation Phosphate-buffered solution

Basic Information

Source Mammalian cells

Purification Mammalian cells

Purity >90% as determined by SDS-PAGE

Immunogen Information

Sequence Amino acid:19-238,with human FC tag.

Target Information

Gene name CD274

Protein Name Programmed cell death 1 ligand 1 (PD-L1) (PDCD1 ligand 1) (Programmed death ligand 1) (hPD-L1) (B7 homolog 1) (B7-H1) (CD antigen CD274)

Organism	Gene ID	UniProt ID
Human	29126 ;	Q9NZQ7 ;

Cellular Localization Cell membrane ; Single-pass type I membrane protein . Early endosome membrane ; Single-pass type I membrane protein . Recycling endosome membrane ; Single-pass type I membrane protein . Nucleus . Note=Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation (PubMed:28813417). Translocates to the nucleus in response to hypoxia via its interaction with phosphorylated STAT3 (PubMed:32929201). .; [Isoform 1]: Cell membrane ; Single-pass type I membrane protein .; [Isoform 2]: Endomembrane system ; Single-pass type I membrane protein .; [Isoform 4]: Secreted .

Tissue specificity Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.; [Isoform 4]: Widely expressed, highest in lung, liver and pituitary and in various peripheral blood cells, including neutrophils and some subtypes of lymphoid and myeloid cells.

Function Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813410, PubMed:28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

| Validation Data

| Contact information

Orders: order@immunoway.com
Support: tech@immunoway.com
Telephone: 877-594-3616 (Toll Free), 408-747-0185
Website: <http://www.immunoway.com>
Address: 2200 Ringwood Ave San Jose, CA 95131 USA



Please scan the QR code to access additional product information:
CD274/PD-L1 recombinant protein

